31.03.23 – Per inaugurated as a member of the Royal Swedish Academy of Sciences
March 2023 – Neurolixis Announces Positive Ph2A Proof-of Concept on NLX-112 in Levodopa-Induced Dyskinesia in Parkinson’s Disease
A Phase IIA clinical trial for treating LID using a novel small molecule performed in collaboration with our clinical team has yielded positive results. Click below to download the full press release.
March 2023 – Meeting in Florida
17.02.2022 Public defense of Yachao He
Visit from Bioarctic team
New grant from Vetenskapsrådet
Funding of 19.96M SEK to conduct an RCT of Montelukast for treating Parkinson’s disease has been awarded to the group. Link for more information can be found here.
Per Svenningsson elected into the Royal Swedish Academy of Sciences
Link to the news article can be found here
New paper on TAAR1 and SEP-856 published in Neuropsychopharmacology
Our paper peeling back the pharmacology behind the new antipsychotic SEP-856 (Ulotaront) can be accessed here
Per Svenningsson elected as a member of Academia Europaea
Link to Per’s page can be found here
